These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29661424)

  • 1. Intravenous Immunoglobulin and Rituximab in HLA Highly Sensitized Kidney Transplant Recipients.
    Querido S; Weigert A; Adragão T; Henriques J; Birne R; Matias P; Jorge C; Nascimento C; Bruges M; Machado D
    Transplant Proc; 2018 Apr; 50(3):723-727. PubMed ID: 29661424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitization Before Living Donor Kidney Transplantation in Highly HLA-Sensitized Patients: A Single-Center Study.
    De Sousa-Amorim E; Revuelta I; Blasco M; Diekmann F; Cid J; Lozano M; Sánchez-Escuredo A; Martorell J; Palou E; Campistol JM; Oppenheimer F
    Transplant Proc; 2015 Oct; 47(8):2332-5. PubMed ID: 26518919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desensitization Protocol in Recipients of Deceased Kidney Donor With Donor-Specific Antibody-Low Titers.
    Kanter Berga J; Sancho Calabuig A; Gavela Martinez E; Puig Alcaraz N; Avila Bernabeu A; Crespo Albiach J; Molina Vila P; Beltrán Catalan S; Pallardó Mateu L
    Transplant Proc; 2016 Nov; 48(9):2880-2883. PubMed ID: 27932097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Year Outcomes of Living Related Kidney Transplant in Patients With Preformed HLA Donor-Specific Antibodies: A Single-Center Experience in Malaysia.
    Jalalonmuhali M; Ng KP; Mohd Shariff NH; Lee YW; Wong AH; Gan CC; Lim SK
    Transplant Proc; 2020; 52(6):1718-1722. PubMed ID: 32448671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailored immunosuppression after kidney transplantation - a single center real-life experience.
    Good-Weber M; Roos M; Mueller TF; Rüsi B; Fehr T
    BMC Nephrol; 2020 Nov; 21(1):501. PubMed ID: 33228545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients: Single-Center Experience.
    Nair P; Gheith O; Al-Otaibi T; Mostafa M; Rida S; Sobhy I; Halim MA; Mahmoud T; Abdul-Hameed M; Maher A; Emam M
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):113-119. PubMed ID: 30777534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Highly Sensitized Patients Undergoing Simultaneous Liver and Kidney Transplantation: A Single-Center Experience With Desensitization.
    Steggerda JA; Kang A; Pan SH; Sundaram V; Nissen NN; Klein AS; Todo T; Annamalai A; Vo A; Jordan SC; Kim IK
    Transplant Proc; 2017; 49(6):1394-1401. PubMed ID: 28736013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study.
    Kim DG; Lee J; Park Y; Kim MS; Jeong HJ; Kim SI; Kim YS; Kim BS; Huh KH
    BMC Nephrol; 2019 Dec; 20(1):456. PubMed ID: 31818254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients.
    Itescu S; Burke E; Lietz K; John R; Mancini D; Michler R; Rose E; Oz M; Edwards N
    Circulation; 2002 Mar; 105(10):1214-9. PubMed ID: 11889016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
    Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney transplantation from HLA-incompatible live donors: Efficiency and outcome of 32 patients after desensitisation.
    Fernández C; Calvo M; Leite N; López A; Ferreiro T; Ribera R; Seijo R; Alonso Á
    Nefrologia; 2017; 37(6):638-645. PubMed ID: 28734583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.